About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients

NCT03829852·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Taipei Veterans General Hospital, Taiwan

With

Chang Gung Memorial Hospital
Koo Foundation Sun Yat-Sen Cancer Center

Age

20–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

mCRC patients who received at least one dose of regorafenib treatment

You may not be if

\<=20 y/o
Patients who did not receive regorafenib treatment will be excluded from the analysis
Patients with incomplete medical records that are deemed ineligible for analysis by investigator

The record

StatusCompleted

PhaseNo phase

Taking part716

StartedFeb 2019

UpdatedJul 23, 2021

Conditions

Metastatic Colorectal Cancer

Where1

Taipei Veterans General Hospital
Taipei, Taiwan

Clareo Health | Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients